Attention Deficit Hyperactivity Disorder (ADHD): Clinical Trials

20 trials for Attention Deficit Hyperactivity Disorder (ADHD), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 4 terminated, 2 recruiting. 20 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 320Completed 14, Terminated 4, Recruiting 2
Phase 22Completed 1, Recruiting 1

Follow Attention Deficit Hyperactivity Disorder (ADHD): new trials by email Literature Review of Attention Deficit Hyperactivity Disorder (ADHD) trials Research Report on Attention Deficit Hyperactivity Disorder (ADHD)

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Long-term Trial of EB-1020 in Adult Patients With ADHD
EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3RecruitingOtsuka Pharmaceutical Co., Ltd.1802025-06-252026-10-23
Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients
EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg, Placebo - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 2 / Phase 3RecruitingOtsuka Pharmaceutical Co., Ltd.6302025-04-302026-10-23
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
Mexidol, Placebo, Mexidol + Placebo - Attention Deficit Hyperactivity Disorder (ADHD), Anxiety Disorders and Symptoms
Phase 3CompletedPharmasoft3332019-07-132025-08-17
Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity
Methylphenidate, Matching Placebo - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3TerminatedAssistance Publique - Hôpitaux de Paris32019-05-072022-04-25
Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
SHP465 - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3TerminatedShire1412018-01-022021-06-03
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
SHP465, Placebo - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3CompletedShire892017-12-092021-06-02
Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Placebo, SPD489 (Lisdexamfetamine dimesylate), SPD489 - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3CompletedShire1992017-09-062021-06-08
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
SPN-810 - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3TerminatedSupernus Pharmaceuticals, Inc.4912016-04-012024-05-16
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
SPN-810 (18 mg), SPN-810 (36 mg), Placebo - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3CompletedSupernus Pharmaceuticals, Inc.2972016-02-162024-03-18
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
SPN-810 (18 mg), SPN-810 (36 mg), Placebo - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3CompletedSupernus Pharmaceuticals, Inc.3332016-01-252024-01-02
Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
SHP465 12.5mg capsules (one capsule daily), Placebo, SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily) - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3CompletedShire2752015-11-192021-06-03
Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder
SPD489 - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3CompletedShire1132015-08-212021-03-05
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
SHP465, Placebo - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3CompletedShire2642015-06-182021-06-03
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
MDX, Placebo - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3TerminatedAlcobra Ltd.2832015-06-012017-01-19
PRC-063 in an ADULT Workplace Environment
PRC-063 25 mg, Placebo, PRC-063 35 mg - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3CompletedRhodes Pharmaceuticals, L.P.602014-08-012015-07-09
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
NT0102, Placebo - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3CompletedNeos Therapeutics, Inc872013-07-012018-01-17
Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe
Extended-release Guanfacine HCl (Intuniv, SPD503) - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3CompletedShire2152012-03-202021-06-16
Train Your Brain and Exercise Your Heart? Advancing the Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
Neurofeedback, Exercise, methylphenidate - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 2 / Phase 3CompletedR. van Mourik1122010-06-012015-12-09
Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
LDX 30 mg, LDX 50 mg, LDX 70 mg - Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3CompletedShire3142008-10-082021-06-14
Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD
Atomoxetine - Fetal Alcohol Syndrome, Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3CompletedUniversity of Oklahoma272005-08-012017-07-02

Narrower conditions

Attention Deficit Disorder with Hyperactivity (20)  ·  Spasm (4)  ·  Anxiety Disorders (1)  ·  Fetal Alcohol Spectrum Disorders (1)  ·  Impulsive Behavior (1)  ·  Marijuana Abuse (1)  ·  Motor Activity (1)  ·  Neurodevelopmental Disorders (1)  ·  Oppositional Defiant Disorder (1)

Broader conditions

Attention Deficit and Disruptive Behavior Disorders (20)  ·  Mental Disorders (20)  ·  Neurodevelopmental Disorders (19)  ·  Nervous System Diseases (4)  ·  Neurologic Manifestations (4)  ·  Neuromuscular Manifestations (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Signs and Symptoms (4)  ·  Behavior (2)  ·  Chemically-Induced Disorders (2)  ·  Substance-Related Disorders (2)  ·  Alcohol-Induced Disorders (1)  ·  Alcohol-Related Disorders (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)

Interventions

Lisdexamfetamine Dimesylate (3)  ·  1-(naphthalen-2-yl)-3-azabicyclo(3.1.0)hexane (2)  ·  Methylphenidate (2)  ·  Atomoxetine Hydrochloride (1)  ·  Biofeedback, Psychology (1)  ·  Exercise (1)  ·  Guanfacine (1)  ·  Neurofeedback (1)  ·  emoxypine succinate (1)

Sponsors

Shire (8)  ·  Supernus Pharmaceuticals, Inc. (3)  ·  Otsuka Pharmaceutical Co., Ltd. (2)  ·  Alcobra Ltd. (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Neos Therapeutics, Inc (1)  ·  Pharmasoft (1)  ·  R. van Mourik (1)  ·  Rhodes Pharmaceuticals, L.P. (1)  ·  University of Oklahoma (1)

Countries

United States (14)  ·  France (2)  ·  Japan (2)  ·  Netherlands (2)  ·  Austria (1)  ·  Belgium (1)  ·  Germany (1)  ·  Ireland (1)  ·  Israel (1)  ·  Italy (1)  ·  Poland (1)  ·  Romania (1)  ·  Russia (1)  ·  Spain (1)  ·  Sweden (1)

Top investigators

Nobuhito Sanada (2)  ·  Anna N. Platonova, Cand.Med.Sci, MD (1)  ·  Anna S. Nezabudkina, MD (1)  ·  Azmi Nasser, PhD (1)  ·  Carolyn Sikes, PhD (1)  ·  Dina D. Gainetdinova, Dr.Med.Sci, Prof. (1)  ·  Elena M. Kryukova, MD (1)  ·  Elena V. Levitina, Dr.Med.Sci, Prof. (1)  ·  Elmira S. Sagutdinova, Cand.Med.Sci, MD (1)  ·  Gianpiera Ceresoli-Borroni, PhD (1)  ·  Irina N. Vakula, MD (1)  ·  Jaap Oosterlaan, Professor (1)  ·  Jeffrey Newcorn, MD (1)  ·  Laura J McGuinn, M.D. (1)

Results publications

PMID 21421179, PMID 26748531, PMID 26771913, PMID 27183299, PMID 27631143, PMID 27866283, PMID 28712074, PMID 28816509, PMID 29098467, PMID 29442229, PMID 32304847, PMID 33185468, PMID 34081560, PMID 35201607, PMID 35230142, PMID 35577034, PMID 40975435